School of Medicine
Showing 1-20 of 388 Results
-
Raj Fadadu
Casual - Non-Exempt, Epidemiology and Population Health
BioRaj Fadadu is currently a dermatology resident physician at the University of California, San Diego. He has experience conducting epidemiology research projects, particularly related to environmental exposures and skin diseases (e.g., atopic dermatitis and psoriasis) as well as epigenetics (e.g., EWAS and epigenetic age acceleration). At Stanford, his research in Dr. Andres Cardenas's group focuses on the relationship between environmental exposures and epigenetic modifications. He also held leadership roles in local and national organizations involved in climate change advocacy and education, working to improve community and patient health. In addition, he is a strong advocate for health equity and increasing access to medical care for people experiencing homelessness and has implemented innovative projects to do so while serving as an Albert Schweitzer Fellow and Director of student-run free clinics in Berkeley, CA. For his impactful work, he was named an Environmental Education "30 Under 30" in 2022 and received the Excellence in Climate Leadership Award from the American Public Health Association in 2022 and Emerging Physician Leader Award from Health Care Without Harm in 2021.
He received a M.D. from UC San Francisco, M.S. degree in Health and Medical Sciences (with concentrations in Environmental Research and Healthcare Management) from the UC Berkeley School of Public Health, and received a B.A. degree in Public Health from UC Berkeley (graduated with Highest Distinction and Research Honors). -
Muneeb A. Faiq
Basic Life Research Scientist, Ophthalmology Research/Clinical Trials
BioDr. Muneeb A. Faiq is a behavioral and metabolic neuroscientist and ophthalmology researcher whose work spans molecular biology, neuroimaging, and systems neuroscience. He has made several foundational contributions, including the first functional cloning of CYP1B1 in congenital glaucoma, implicating retinoic-acid signaling in Zika virus–associated microcephaly, identifying central insulin resistance as a mechanistic basis for glaucoma, and providing the first in vivo evidence for a glymphatic pathway in the optic nerve. With more than 100 peer-reviewed publications and over 4,000 citations, Dr. Faiq has earned international recognition, including the Emerging Vision Scientist Award – 2019 from the Alliance for Eye and Vision Research. He is widely regarded as the pioneer and principal architect of the discipline of psychosomatic ophthalmology, a field he helped conceptualize and establish, leading to the integration of ophthalmic clinical practice with mindfulness-based and psychosomatic medicine frameworks. Dr. Faiq is currently advancing the concept of neurometabolic syntax in vision and brain function — a unifying systems-level framework that integrates genetics, metabolism, and behavior to reconceptualize ophthalmic and neurological diseases through a mechanistic and interdisciplinary lens. He has been selected for the prestigious Asia Pacific Academy of Ophthalmology (APAO) Achievement Award 2026.
-
Robert Michael Fairchild
Assistant Professor of Medicine (Immunology and Rheumatology)
Current Research and Scholarly InterestsDr. Fairchild’s research focuses on musculoskeletal and organ-based ultrasound in rheumatic disease, including arthritis, calcinosis, vascular pathology, and interstitial lung disease. He develops ultrasound-based outcome measures and leads projects applying deep learning and explainable AI to imaging. He also performs ultrasound-guided synovial biopsies to support translational and clinical research.
-
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
BioDr. Bita Fakhri is an Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, Richter’s syndrome, and other hematologic malignancies.
As a clinical scientist, Dr. Fakhri is dedicated to patient care, trainee education, and the development of novel therapies for individuals with CLL/SLL. She has co-authored numerous publications focusing on CLL, targeted therapies, and cellular therapies in hematologic malignancies.
Dr. Fakhri currently serves as Director of the CLL Clinical Trial Portfolio at Stanford. In addition, she is actively involved in building infrastructure to expand access to clinical trials and promote equity in care for underserved and marginalized populations across the Stanford catchment area. -
Titilola Falasinnu
Assistant Professor of Medicine (Immunology and Rheumatology) and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult Pain)
BioI am primarily a lupus researcher and identify as a pain scientist and methodologist in this field. Systemic lupus erythematosus (SLE) disproportionately affects women and racial minorities and is the fifth most common cause of death among 15- to 24-year-old Black and Hispanic women in the U.S., highlighting its significant public health impact. More than half of patients with SLE experience chronic pain, often secondary to SLE itself or overlapping conditions (e.g., migraines, low back pain, fibromyalgia), contributing significantly to disability and impaired quality of life. Chronic pain is not merely a symptom but a disease in its own right—one that deserves the same rigorous study and clinical attention as comorbidities like kidney disease and cardiovascular disease in rheumatology. The enormous global burden of chronic pain underscores the urgent need for a clear, standardized definition of pain as a disease, particularly in autoimmune rheumatic diseases where pain can arise from inflammatory, nociplastic, and biopsychosocial mechanisms. Without recognizing pain as a distinct disease entity, its mechanisms remain poorly understood, and effective treatment strategies remain underdeveloped.
I am a co-Principal Investigator of the Pain Intelligence Lab, where our mission is to advance the study of pain as a disease in rheumatology through two primary objectives. First, we develop and validate computational methods that enable clinicians and researchers to leverage electronic health records, administrative claims, and disease registries to study chronic pain as a distinct disease entity in rheumatology. By applying machine learning, natural language processing, and real-world data analysis, we seek to enhance pain phenotyping, classify distinct pain subtypes, and develop predictive models for treatment response. Second, we use a biopsychosocial framework to examine the predictive power of biomarkers and psychosocial measures in rheumatologic pain. By integrating biological, psychological, and social determinants of pain, we aim to conduct rigorous, patient-oriented research that translates targeted assessments into mechanistically informed, personalized treatment approaches for optimized clinical care. Ultimately, my long term career goal is to bridge the gap between research and clinical practice, ensuring that pain management in autoimmune rheumatic diseases is precise, equitable, and optimized for improved patient outcomes. -
Ryann Fame, PhD
Assistant Professor of Neurosurgery
Current Research and Scholarly InterestsEarly neural progenitors respond to extrinsic cues that maintain and support their potency. These stem/ progenitor cells are in direct contact with the cerebrospinal fluid (CSF), which acts as part of their niche. Our research program encompasses the early neural stem cell niche, neural tube closure, CSF, metabolism, and cortical neuronal development. We are dedicated to broad collaboration focused on translating an understanding of neurodevelopment and CSF biology into regenerative strategies.
-
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
